Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of BCT301 (Anti-CD19 Chemically Induced Pluripotent Stem Cell (CiPSC)-Derived CAR-iT Cells) Therapy for Refractory Autoimmune Diseases

NCT07301164 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT07301164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07301164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of BCT301 (Anti-CD19 Chemically Induced Pluripotent Stem Cell (CiPSC)-Derived CAR-iT Cells) Therapy for Refractory Autoimmune Diseases
Lead sponsor
Peking University Third Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
December 11, 2025
Completion date
December 31, 2028
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anca associated vasculitis, antiphospholipid syndrome, inflammatory myositis, sjogren syndrome, system lupus erythematosus, systemic sclerosis (ssc)